Authors

Latest:

Initiative Seeks to Advance Molecular Understanding of Pancreatic Cancer

A partnership between the Pancreatic Cancer Action Network and Perthera, a self-described "concierge" for molecular diagnostic testing, is aiming to give patients with this hard-to-treat cancer the ability to determine the best course of treatment.

Mary K. Caffrey, from AJMC.com

Latest:

Myriad CEO Discusses Reimbursement Hurdles in Molecular Testing

Mark C. Capone discusses the challenges and opportunities in molecular diagnostics, and what's ahead at Myriad Genetics.

Mary Kruczynski

Latest:

The Community Option: The Road Less Traveled

As we advance toward producing an integrated cancer model, the value of the practicing community oncologist has revealed itself to be an integral piece of the puzzle.

Mary L. (Nora) Disis, MD

Latest:

Dr. Disis on the Rationale For Investigating PRGN-3005 With/Without Lymphodepletion in Ovarian Cancer

Mary “Nora” Disis, MD, discusses the rationale for investigating the efficacy and optimal delivery of PRGN-3005 autologous UltraCAR T cells in patients with advanced stage platinum-resistant ovarian cancer.

Mary Lou Woodford, RN, BSN, MBA, CCM

Latest:

Mary Lou Woodford on CoC Accreditation Compliance

Mary Lou Woodford, from the Cancer Resource Foundation, provides guidance on staying compliant with the new patient navigation accreditation standards from the American College of Surgeons Commission on Cancer.

Mary S. Dietrich, MS, PhD, Anthony Cmelak

Latest:

PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck Radiation

A feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.

Maryam Nemati Shafaee, MD

Latest:

Dr. Shafaee on the Value of Biosimilars

Maryam Nemati Shafaee, MD, assistant professor, Duncan Cancer Center, Lester & Sue Smith Breast Cancer, Baylor College of Medicine, discusses the value of biosimilars in oncology.

Maryann J. Kwa, MD

Latest:

Dr. Kwa on the TAILORx Trial in Breast Cancer

Maryann J. Kwa, MD, instructor, Department of Medicine, NYU Langone’s Perlmutter Cancer Center, discusses the results of the TAILORx trial in breast cancer.

MaryBeth Freeman, MPH

Latest:

Updated Screening Guidelines in Prostate Cancer

MaryBeth Freeman, MPH, senior associate scientist, Surveillance Research, American Cancer Society, discusses updated screening guidelines in prostate cancer.

Masanori Terashima, MD, PhD, FACS

Latest:

Dr. Terashima on Future of Bursectomy and Omentectomy for Gastric Cancer

Masanori Terashima, MD, PhD, FACS, Shizuoka Cancer Center, chairman of the Japanese Clinical Oncology Group, discusses the future of bursectomy and omentectomy for patients with gastric cancer.

Masatoshi Kudo, MD, PhD

Latest:

Refining First-Line Immunotherapy Strategies in Hepatocellular Carcinoma: With Masatoshi Kudo, MD, PhD

Masatoshi Kudo, MD, discusses the evolving treatment landscape in HCC and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens.

Masatoshi Kudo, MD, PhD, Kindai University

Latest:

Future Directions of HCC

Stephen L. Chan, MD; Masatoshi Kudo, MD, PhD; and Amit Singal, MD, discuss the future treatment landscape for the management of HCC (hepatocellular carcinoma).

Masatoshi Kudo, MD, PhD, Kindai University Faculty of Medicine

Latest:

Optimizing Treatment Strategies in R/R Hepatocellular Carcinoma

Massimo Cristofanilli, MD

Latest:

Dr Cristofanilli on the Next Steps With Camizestrant in HR+/HER2– Breast Cancer

Massimo Cristofanilli, MD, discusses the next steps with camizestrant in ESR1-mutated HR-positive, HER2-negative advanced breast cancer.

Massimo Cristofanilli, MD, FACP

At Weill Cornell Medicine and NewYork-Presbyterian, Dr. Cristofanilli serves as the Associate Director of Precision Oncology at the Meyer Cancer Center (MCC), and the co-leader of the MCC Breast Cancer Disease Management Team, as well as the Scientific Director of the Englander Institute of Precision Medicine (EIPM).

Latest:

Dr Cristofanilli on the Potential Role of Serial ESR1 Mutation Monitoring in HR+/HER2-Negative Advanced Breast Cancer

Massimo Cristofanilli, MD, details the implications of serial ESR1 mutation monitoring using ctDNA in HR-positive/HER2-negative advanced breast cancer.

Massimo Di Maio, PhD

Latest:

Importance of Quality of Life Endpoints in Clinical Trials

Massimo Di Maio, PhD, medical oncologist, Mauriziano Hospital, professor of medical oncology, University of Turin, discusses the importance of quality of life (QoL) endpoints in clinical trials.

Materials Provided by Children's Hospital Boston

Latest:

New Angiogenesis Inhibitor May Be Effective Against a Broad Range of Cancers

Researchers at Children's Hospital Boston say that they have developed the first oral, broad-spectrum angiogenesis inhibitor that may offer a potential nontoxic therapy for a wide range of cancers. The drug was formulated through nanotechnology and has shown promising anticancer results in mice.

Mateusz Opyrchal, MD, PhD

Latest:

Dr. Opyrchal on the Current State of Biomarkers in TNBC

Mateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.

Mathew Hall, MD

Latest:

Dr. Mathew Hall on the Impact of PSA Screening Recommendations

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

Mathias J. Rummel, MD, PhD

Latest:

Dr. Rummel on the Chemical Structure of Bendamustine

Dr. Mathias Rummel, from the University Hospital Giessen in Germany, on the Bendamustine Chemical Structure